<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253980</url>
  </required_header>
  <id_info>
    <org_study_id>095/2010</org_study_id>
    <secondary_id>PACTR201201000259370</secondary_id>
    <nct_id>NCT01253980</nct_id>
  </id_info>
  <brief_title>Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children</brief_title>
  <official_title>The Efficacy of Prophylactic Antibiotics in the Management of Pneumonitis Following Paraffin (Kerosene) Ingestion in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cape Town</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paraffin (kerosene) ingestion in the developing world accounts for a large number of visits
      to healthcare facilities, especially amongst children. There is no evidence in animals and no
      good evidence in humans that the use of early antibiotics improves the clinical outcome of
      paraffin-induced pneumonitis. This randomised placebo-controlled trial will investigate
      whether the use of early antibiotics affects the clinical course of children with pneumonitis
      following paraffin ingestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The average of 100 children per annum attending Red Cross War Memorial Children's Hospital
      9RCWMCH) with the diagnosis of kerosene ingestion would give a sample of 200 children over a
      two-year period, with 100 patients in each group. From a postulated secondary infection rate
      of 15 to 50% for children not receiving an antibiotic, a midway point of 25% estimated the
      treatment failure rate in the placebo group. With no information available on the treatment
      failure rate in the active group, failure rates of 10% and 5% were arbitrarily applied. With
      25% and 5% treatment failure rates for placebo and active groups respectively, at a level of
      significance of α = 0.05 a sample size of 100 per group gives a power of 0.98 and with
      failure rates of 25% and 10% a power of 0.80.

      Statistical analysis was done using IBM SPSS Version 20 (SPSS Inc., Chicago, IL, USA).
      Categorical variables are expressed as n (%) and continuous variables as median
      (interquartile range (IQR)). A P value of ≤ 0.05 was considered significant for all
      situations. For categorical variables, Fischer's exact test was used for small samples or
      less frequent occurrences. Chi-Square testing was applied for larger samples or more frequent
      occurrences. Mann-Whitney or Kruskal-Wallis tests were used for ordinal and continuous
      variables. Significant correlation between factors and covariates (Spearman's rank
      coefficient) favoured univariate analysis over binary logistic regression modelling to
      determine potential risk factors for treatment failure. Continuous variables were categorised
      for clinical relevance or logistic regression testing. In some instances, specific clinical
      parameters or reported symptoms were not recorded or the presence or absence of a risk factor
      was unknown. The missing values, unknown factors and the flow of patient follow-up account
      for totals not always adding up to the full number of study participants. In the results for
      Day 3 and Day 5 post-ingestion, the denominator used to calculate proportions for reported
      symptoms included those patients who attended and who were telephone interviewed, whereas the
      denominator for clinical signs was only the patients who attended.

      The primary outcome measure was treatment failure, as reported. Secondary outcome measures
      were length of hospital stay, reported symptoms (cough, shortness of breath, wheeze and
      fever) and clinical signs (respiratory rate, flaring, recessions, grunting, wheeze,
      crepitations, temperature and altered mental status) at follow-up at Day 3 and 5
      post-ingestion for placebo and active groups. Further investigation explored the role of
      confounding conditions (upper respiratory tract infection, active Mycobacterium tuberculosis
      infection) and risk factors for treatment failure or delayed resolution (vomiting
      post-ingestion, household smoking contact, HIV exposure status, prior respiratory history,
      young age etc). Secondary outcome measures, confounding conditions and risk factors are not
      reported in this Clinical Trials format, but are reported in the PI's Master's thesis. (Balme
      KH. The efficacy of prophylactic antibiotics in the management of pneumonitis following
      paraffin (kerosene) ingestion in children [Master's thesis]. [Cape Town]: University of Cape
      Town; 2013. 113 p.)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure</measure>
    <time_frame>At routine follow-up 3 and 5 days post-ingestion or earlier if necessary</time_frame>
    <description>A treatment failure was a patient who at any time deteriorated necessitating a change to the treatment regimen. This was determined by assessing reported symptoms (cough, shortness of breath, wheeze and fever) and comparing clinical signs (respiratory rate, oxygen saturation, wheeze, flaring, grunting, recessions, crepitations, temperature, mental status) to signs at presentation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Kerosene Pneumonitis</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days</description>
    <arm_group_label>Amoxicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.
Dose 20-30mg/kg 8 hourly for 5 days</description>
    <arm_group_label>Placebo suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ingestion in the preceding 24 hours

          -  Presence of respiratory symptoms and/or signs at presentation

          -  Informed consent obtained from parent or legal guardian

          -  Resident within the Red Cross Hospital drainage area and able to come for two
             follow-up appointments

        Exclusion Criteria:

          -  Asymptomatic and no clinical signs

          -  Too ill to be excluded from receiving an antibiotic as judged by:

               -  Requiring more than 2L/min nasal-prong oxygen

               -  Requiring continuous or intermittent positive airway pressure ventilation

               -  Fever &gt; 40˚C

          -  Needing an antibiotic for another reason e.g. otitis media, tonsillitis

          -  Current antibiotic use, prior to kerosene ingestion

          -  Allergic to amoxicillin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Zar, MBBCh PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael D Mann, MMed Paed PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Balme KH, Zar H, Swift DK, Mann MD. The efficacy of prophylactic antibiotics in the management of children with kerosene-associated pneumonitis: a double-blind randomised controlled trial. Clin Toxicol (Phila). 2015;53(8):789-96. doi: 10.3109/15563650.2015.1059943. Epub 2015 Jun 26.</citation>
    <PMID>26114347</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2010</study_first_posted>
  <results_first_submitted>May 6, 2013</results_first_submitted>
  <results_first_submitted_qc>May 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2013</results_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cape Town</investigator_affiliation>
    <investigator_full_name>Kate Balme</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>pneumonitis</keyword>
  <keyword>paraffin</keyword>
  <keyword>kerosene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 21 July 2010 - 21 September 2011 (24 hours a day) Patients recruited from Medical Emergency Department</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo 20-30mg per kg 8 hourly for 5 days</description>
        </group>
        <group group_id="P2">
          <title>Amoxicillin</title>
          <description>Amoxicillin 20-30mg per kg 8 hourly for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo 20-30mg per kg 8 hourly for 5 days</description>
        </group>
        <group group_id="B2">
          <title>Amoxicillin</title>
          <description>Amoxicillin 20-30mg per kg 8 hourly for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="B2" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B3" value="19" lower_limit="16" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure</title>
        <description>A treatment failure was a patient who at any time deteriorated necessitating a change to the treatment regimen. This was determined by assessing reported symptoms (cough, shortness of breath, wheeze and fever) and comparing clinical signs (respiratory rate, oxygen saturation, wheeze, flaring, grunting, recessions, crepitations, temperature, mental status) to signs at presentation.</description>
        <time_frame>At routine follow-up 3 and 5 days post-ingestion or earlier if necessary</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 20-30mg per kg 8 hourly for 5 days</description>
          </group>
          <group group_id="O2">
            <title>Amoxicillin</title>
            <description>Amoxicillin 20-30mg per kg 8 hourly for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure</title>
          <description>A treatment failure was a patient who at any time deteriorated necessitating a change to the treatment regimen. This was determined by assessing reported symptoms (cough, shortness of breath, wheeze and fever) and comparing clinical signs (respiratory rate, oxygen saturation, wheeze, flaring, grunting, recessions, crepitations, temperature, mental status) to signs at presentation.</description>
          <population>per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="3" upper_limit="22"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.50</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative risk</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <desc>The study was not testing a new drug, but rather reviewing efficacy of a known drug compared to placebo. Drug was not given to children with known allergy to amoxicillin. There were no idiosyncratic drug reactions. No children had events which could be linked to the study drug; any clinical findings were related to the kerosene pneumonitis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo 20-30mg per kg 8 hourly for 5 days</description>
        </group>
        <group group_id="E2">
          <title>Amoxicillin</title>
          <description>Amoxicillin 20-30mg per kg 8 hourly for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of participants. Some patients did not attend follow-up and were only contacted by phone, therefore clinical data not available for all participants at follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Kate Balme</name_or_title>
      <organization>Poisons Information Centre, Red Cross War Memorial Children's Hospital and University of Cape Town</organization>
      <phone>+27 21 658 5308</phone>
      <email>kate.balme@uct.ac.za</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

